# A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

> **NCT01572519** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 21 (actual)

## Conditions studied

- Relapsed or Refractory Hodgkin Lymphoma

## Interventions

- **DRUG:** Phase 1, Cohort 1
- **DRUG:** Phase 1, Cohort 2
- **DRUG:** Phase 1, Cohort 3
- **DRUG:** Phase 1, Cohort 4
- **DRUG:** Phase 2

## Key facts

- **NCT ID:** NCT01572519
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-17
- **Primary completion:** 2013-08-13
- **Final completion:** 2013-08-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01572519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01572519, "A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01572519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*